Pharma BD Deal Intelligence
Iclusig became a durable niche hematology earner, but brigatinib (Alunbrig) — the deal's real thesis at $1B+ peak-sales projection — was crushed by Alecensa and never came close, leaving a weak return on the $5.2B price.
Full analysis, sources & comparables →Takeda's $5.2B Ariad bid, announced at JPMorgan, signals an aggressive oncology buildout — pairing marketed Iclusig with near-term launch asset brigatinib.
Takeda projected the acquisition would be accretive to Underlying Core Earnings by FY2018, framing the deal as a strategic expansion of its global oncology and…
Morgan Stanley MUFG analyst Shinichiro Muraoka cautioned that Iclusig and brigatinib sit in the 'third-fourth order groups' of their respective markets and…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Takeda agreed to acquire ARIAD for $24.00/share in cash, an enterprise value of approximately $5.2B representing a ~75% premium. The deal expanded Takeda's oncology and hematology business with two targeted therapies: marketed Iclusig in CML and Phase 3 brigatinib in NSCLC. Acquisition completed February 16, 2017.
Iclusig became a durable niche hematology earner, but brigatinib (Alunbrig) — the deal's real thesis at $1B+ peak-sales projection — was crushed by Alecensa and never came close, leaving a weak return on the $5.2B price.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals (this deal) | 2017 | $5.2B | 47 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2017 deals · Takeda Pharmaceutical Company Ltd. deals · Hematology deals